NASDAQ NMS - GLOBAL MARKET · CLDX
-4.21% · -$1.28 · Vol 4.0M
Market closed · last close 4:00 PM ET · price as of 17:14:24 ET
Celldex Therapeutics Inc

Celldex Therapeutics Inc

Biotechnology
$29.15
Card
Relationship Map

Follow $CLDX

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $CLDX by email

Veridion Score

BETAHIGH CONF · 6 of 6 factors measuredMethodology
CLDX
Celldex Therapeutics Inc
Thu Oct 8 · last completed session · Markets closed · resumes Fri 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

45/ 100
Veridion Score
Middle range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Thu Oct 8 · last completed session · Markets closed · resumes Fri 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is CLDX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading CLDX catalysts
About Celldex Therapeutics Inc
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Listed since
1986
Employees
198
Country
US

Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$30.07
Day high
$30.10
Day low
$28.63
Previous close
$30.43
52W high
$44.87
-35.03% from high
52W low
$22.58
29% of range
Market cap
$2.4B
EPS
$-3.9800
Beta
0.46
Shares out
78.5M
Volume
4M
2.20× rel vol
Avg volume
1.8M
VWAP
$29.22
Price history computed in-house
1W
-7.90%
1M
-24.83%
3M
-25.47%
1Y
+5.85%
YTD
+7.33%
SMA 50 $37.87 · below
SMA 200 $32.43 · below
52W position 29%

CLDX overview

Veridion Score
45
Registered · 2026-10-08
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around CLDX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading CLDX Form 4 filings
Public disclosures

Congress activity in CLDX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

CLDX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CLDX in this window.
Lobbying spend

CLDX lobbying filings, year to date.

Registered lobbying filings matched to Celldex Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CLDX in this window.
Loading news for CLDX
Analyst ratings
Sovereign unlock shows live analyst consensus for CLDX.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.